Related Experiment Videos
New antibiotics
1Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas 75235-9063, USA.
Abstract:
Three broad-spectrum antibiotics are reviewed, each from a different class. Meropenem is closely related to imipenem and was recently approved for use in children. Its advantages over imipenem include greater activity against gram-negative bacteria and lack of association with seizures. Cefepime is a fourth generation cephalosporin with the gram-positive activity of cefotaxime and the gram-negative spectrum of ceftazidime. Trovafloxacin is a fluoroquinolone with an exceptionally broad antibacterial spectrum. Meropenem is approved for use in children, cefepime is approved for use in adults only, and trovafloxacin is still undergoing clinical trials. These agents should be reserved for treatment of serious infections, especially those in immunocompromised patients or polymicrobial infections.
Insights
This review covers three broad-spectrum antibiotics: meropenem, cefepime, and trovafloxacin. These powerful antibacterial agents are best reserved for severe infections, particularly in immunocompromised patients.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Review of three distinct classes of broad-spectrum antibiotics.
- Focus on meropenem, cefepime, and trovafloxacin for treating serious bacterial infections.
Purpose of the Study:
- To compare the characteristics and clinical applications of meropenem, cefepime, and trovafloxacin.
- To highlight the advantages and limitations of each antibiotic in pediatric and adult populations.
Main Methods:
- Literature review of pharmacological properties and clinical trial data.
- Comparative analysis of antibacterial spectrum, efficacy, and safety profiles.
Main Results:
- Meropenem shows improved gram-negative activity and reduced seizure risk compared to imipenem, approved for children.
- Cefepime (fourth-generation cephalosporin) offers broad gram-positive and gram-negative coverage, approved for adults.
- Trovafloxacin (fluoroquinolone) possesses an exceptionally wide antibacterial spectrum but is still in clinical trials.
Conclusions:
- Meropenem, cefepime, and trovafloxacin represent significant advancements in treating serious infections.
- Judicious use is recommended, especially for immunocompromised patients and polymicrobial infections.
- Availability and approval status vary, impacting clinical decision-making.